



一、会议时间 TIME

2023年12月3日 (星期日)

December 3rd, 2023

二、会议地点 VENUE

武汉·光谷皇冠假日酒店长江厅

Yangtze River Banquet Hall,
Wuhan OVC Crowne Plaza Hotel

三、举办方 ORGANIZERS

主办单位 武汉产业创新发展研究院

协办单位 中国科学院上海药物研究所
塞尔维亚贝尔格莱德大学
"Siniša Stanković"生物研究所

Host: Wuhan Institute of Industrial Innovation and Development (WHIID)

Sponsors: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Institute for Biological Research, "Siniša Stanković"
National Institute of the Republic of Serbia, University of Belgrade



四、举办方领导 EXECUTIVE REPRESENTATIVES



Marina Soković

塞尔维亚贝尔格莱德大学
“Siniša Stanković”
生物研究所 (IBISS) 研究员

Marina Soković, Research Fellow of
Institute for Biological Research,
“Siniša Stanković” National Institute
of the Republic of Serbia, University
of Belgrade (IBISS), Serbia



叶阳 Ye Yang

中国科学院上海药物所 党委书记、副所长、研究员

Ye Yang, Party Secretary, Deputy
Director and Research Fellow,
Shanghai Institute of Materia Medica,
China Academy of Sciences



李锡玲 Li Xiling

武汉产业创新发展研究院 院长

Li Xiling, President of Wuhan Institute
of Industrial Innovation and Development

五、会议主题 THEME

第三期东湖科学会议聚焦“天然产物与新药发现”，参会方将探讨在重大慢病、新发突发病毒性传染病领域基于天然产物和传统药物的生物活性发现以及基于活性化合物的新药发现，分享成果转化案例和实践，推动生物医药领域国际合作，推进合作解决未满足的临床用药需求；促进中国与泛巴尔干地区天然产物研究与新药研发科研机构、高校和企业界交流；促进建设国际规范的综合性创新药物研发体系，提升新药研发水平；共同探索成果转化新模式，建立联合人才培养机制，促进跨地区合作交流和成果转化。

The 3rd session of the Donghu Science Symposium, themed "Natural Products and New Drug Discovery", participants will discuss the discovery of bioactivity in major chronic diseases and emerging viral infectious diseases. The emphasis is on natural products and traditional medicines, as well as the discovery of new drugs based on active compounds. The conference aims to share cases and practices of result transfer and translation, explore and accelerate international cooperation in the field of biomedicine, and collaborate to address unmet clinical drug needs.

It also seeks to facilitate exchanges between research institutions, universities in China and the wider Balkan region in the research and development of natural products and new drugs. The conference aims to promote the construction of a comprehensive innovative drug development system in accordance with international standards, enhancing the level of new drug development. Furthermore, it encourages the exploration of new models for result transfer and translation, the establishment of joint talent cultivation mechanisms, and the promotion of cross-regional cooperation, exchange, and result transfer and translation.

六、会议议程 AGENDA

议 程			
时间	致 辞		主持人
14:30-14:50	武汉产业创新发展研究院院长李锡玲 致欢迎辞		戴月 武汉产业创新发展研究院 院长助理
	中国科学院上海药物所党委书记、副所长、研究员叶阳 致辞		
	塞尔维亚IBISS研究员Marina Soković 致辞		
学术交流		报告人	戴月 武汉产业创新发展研究院 院长助理
14:50-15:05	分子中具有孤立手性模块的天然与合成杂环化合物的手性光学分析	Tibor Kurtán 匈牙利德布勒森大学教授	
15:05-15:20	淡水海绵 <i>Ephydatia fluviatilis</i> 作为潜在天然抗菌剂的研究	Ana Ćirić 塞尔维亚IBISS首席研究员	
15:20-15:30	休 息		
成果转化交流报告		报告人	主持人
15:30-15:45	武创院科技成果转化创新模式探索	王慧中 武汉产业创新发展研究院院长助理	叶阳 中国科学院上海药物研究所党委书记、副所长、研究员
15:45-16:00	产医融合—推进创新靶标发现有序突破	曹跃琼 武创院创新靶点药物研究所所长, 上海吉凯基因医药科技股份有限公司董事长	
16:00-16:30	武创院天然产物与新药发现研究所建设方案	叶阳 中国科学院上海药物研究所党委书记、副所长、研究员	
16:30-18:00	研讨发言		
18:00-20:00	会议晚宴		

Events			
Time	Speeches		Moderator
14:30-14:50	Welcome speech by Li Xiling, President of Wuhan Institute of Industrial Innovation and Development	Dai Yue Assistant President of WHIID	Dai Yue Assistant President of WHIID
	Speech by Ye Yang, Party Secretary, Deputy Director and Research Fellow, Shanghai Institute of Materia Medica, China Academy of Sciences		
	Speech by Marina Soković, Research Fellow of IBISS		
Academic exchange		Presenter	Dai Yue Assistant President of WHIID
14:50-15:05	Chiroptical analysis of natural and synthetic heterocycles with isolated blocks of chirality	Tibor Kurtán Professor, University of Debrecen, Hungary	
15:05-15:20	The freshwater spongy <i>Ephydatia fluviatilis</i> as potential natural antimicrobial agent	Ana Ćirić Principal Research Fellow of IBISS, Serbia	
15:20-15:30	Break		
Presentations on translation of research findings		Presenter	Moderator
15:30-15:45	Exploration of Innovative Modes for the translation of research findings in WHIID	Wang Huizhong Assistant President of WHIID	Ye Yang Party Secretary, Deputy Director and Research Fellow, Shanghai Institute of Materia Medica, China Academy of Sciences
15:45-16:00	Integration of industry and medicine: promoting breakthroughs in the discovery of innovative targets	Cao Yueqiong Director of the WHIID Institute of Innovative Target Drugs, Chairman of Shanghai Genechem Co., LTD	
16:00-16:30	Report on the development plan of the Institute of Natural Products and New Drug Discovery of WHIID	Ye Yang Party Secretary, Deputy Director and Research Fellow, Shanghai Institute of Materia Medica, China Academy of Sciences	
16:30-18:00	Discussion		
18:00-20:00	Banquet		

七、特邀专家 INVITED EXPERTS



Ermias Dagne Haile

非洲科学院、发展中国家科学院院士

Academician of African Academy of Sciences, Academy of Sciences for Developing Countries

生于1944年，于美国加州大学获得博士学位，系埃塞俄比亚知名研究团队负责人。创办了企业Aritiherbal，主要向当地和国际市场提供药用植物、提取物与各种增值天然产品。牵头负责多功能数据库Alnapnetwork，广受各方欢迎。

Ermias Dagne Haile was born on June 8, 1944, got his PhD in the University of California, USA. He is emeritus and leader of a very active research group in Ethiopia. He and his wife run a natural products business: www.aritiherbal.com that brings herbs, extracts, and a wide array of value added natural products to local and international markets. He leads a popular and versatile database: www.alnapnetwork.com.



Sokol Abazi

阿尔巴尼亚加拿大理工学院校长

Prof. Dr. Rector of Canadian Institute of Technology

先后就读于阿尔巴尼亚地拉那大学工业化学专业与瑞士弗里堡大学有机合成专业，1998年于牛津大学从事天然产物全合成博士后研究，曾在英国与瑞士多家天然产业相关企业就职，后于阿尔巴尼亚地拉那大学任教授。2015年以来，担任加拿大理工学院教授，自2020年起担任校长职务。主要研究方向为天然产物、有机合成、超临界流体萃取（SFE）。

Sokol Abazi graduated as Industrial Chemist in Albania, Tirana University in 1989. In 1997 he obtained his PhD from Fribourg University (Switzerland) in organic synthesis. After a Postdoc in Total Synthesis of Natural Products at Oxford University in 1998, he worked for a couple of companies in the UK and Switzerland and then returned to Albania 2008 working as a Full Professor at Tirana University. Since 2015 he is a Full Professor at CIT, where from 2020 he holds the Rector position. His research interests are mainly focused on natural products, organic synthesis, and supercritical fluid extraction (SFE).



Viktor Nedovic

塞尔维亚加速创新创业工程负责人、贝尔格莱德大学农业系教授

Director of Serbia Accelerating Innovation and Entrepreneurship Project, Professor at the Faculty of Agriculture University of Belgrade

塞尔维亚科技发展和创新部SAIGE-加速创新创业工程负责人，曾任科技发展和创新部部长助理及国务秘书，系贝尔格莱德大学农业学院食品技术和生物化学系全职教授。

Director of Serbia Accelerating Innovation and Entrepreneurship Project – SAIGE, Ministry of Science, Technological Development and Innovation (in the past, spent more than 10 years on the positions of Assistant Minister and State Secretary in the Ministry responsible for science and innovation). He is also a full Professor at the Dept. of Food Technology and Biochemistry, Faculty of Agriculture, University of Belgrade.



Antoaneta Borissova Trendafilova

保加利亚科学院植物化学中心有机化学研究所教授

Professor of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences (IOCCP).

就读于索非亚大学化学系，于1997年获保加利亚科学院植物化学中心有机化学研究所博士学位。自1992年起任教于保加利亚科学院，研究领域为天然产物化学。发表科研论文108篇，被引780次以上，h指数14；参与DFG、UNESCO、SNF、H2020等国际项目8项，BAS双边项目8项，国家项目30余项(NSF支持)。负责2个塞尔维亚国家级项目及6个与埃及科学院等合作的双边项目。

Graduated from Faculty of Chemistry, Sofia University, 1991; Obtained PhD in 1997 from the Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences (IOCCP-BAS). Work in IOCCP-BAS since 1992. Experience in natural product chemistry – isolation, structural determination and analysis of biologically active natural compounds. 108 scientific articles with more than 780 citations, H-index 14; Participant in 8 international projects, supported by DFG, UNESCO, SNF, H2020, etc., 8 bilateral projects of BAS and more than 30 national projects (supported by NSF). Coordinator of 2 national projects and 6 bilateral projects of BAS with Serbian and Egyptian Academies of Sciences, TUBITAK.



Tibor Kurtán

匈牙利德布勒森大学教授，有机化学系系主任

Professor and department chair at the
Department of Organic Chemistry,
University of Debrecen, Hungary

2001年获得博士学位，现任教于匈牙利德布勒森大学有机化学系，教授、系主任。主要研究方向为具有潜在药理活性的黄酮类化合物及其类似物，以及含O, N原子的杂环化合物的立体选择性合成和立体化学研究，利用手性光学方法在溶液和固态状态下对分离的与合成的有机化合物进行立体化学分析，以及固态环境下对分离的与合成的有机化合物进行立体化学分析。

Tibor Kurtán received his Ph.D. degree in 2001 and currently he is a full professor and department chair at the Department of Organic Chemistry, University of Debrecen, Hungary. His research interest is the stereoselective synthesis and stereochemical study of flavonoids, related analogues and O,N-heterocycles with potential pharmacological activities. He also utilizes chiroptical methods for the stereochemical analysis of isolated and synthetic organic compounds in solution and solid-state.



Gjoshe Stefkov

北马其顿斯科普里大学药学院科学与国际合作副院长、教授

Full professor and Vice Dean for
Science and International Cooperation
of Cyril and Methodius University in
Skopje, Republic of North Macedonia.

欧洲药典MAP专家组13B的成员，曾承担各类项目科研委托，如马其顿食品和兽医局的食物补充剂营销授权、马其顿医药局的药品分类、马其顿医药局的传统草药营销授权、马其顿医药局的GMP项目、卫生部的大麻种植许可、麻醉药品和精神药物管制法研究等。欧洲药用和芳香植物遗传资源保护合作项目国家协调员，马其顿制药协会、马其顿生态学会和AMAPSEEC成员。

Gjoshe Stefkov has been a member of the MAP expert group 13 B within the European pharmacopeia. He received various commissions such as Marketing Authorization of Food Supplements within Macedonian Agency for Food and Veterinary, Classification of Pharmaceuticals within Macedonian Medicine Agency, Marketing Authorization of Traditional Herbal Medicine within Macedonian Medicine Agency, GMP within Macedonian Medicine Agency, Cannabis cultivation licensing within Ministry of Health, Law on Control of Narcotic Drugs and Psychotropic Substances. He also serves as National coordinator for European Cooperative Programme of Plant Genetic Resources Conservation for Medicinal and Aromatic plants, and is a member of the Macedonian Pharmaceutical Association, Macedonian Ecological Society and the AMAPSEEC.



Ana Ćirić

塞尔维亚IBISS首席研究员

Principal Research Fellow of
IBISS-National Institute of Republic of Serbia

塞尔维亚贝尔格莱德大学"Siniša Stanković"生物研究所(IBISS)首席研究员。研究方向为从植物等天然及合成化合物中分离多种生物活性物质，及某些化合物在生物转化中的新型代谢途径。参与多个国际国内项目，发表科研论文204篇，被引用次数超过5000次，h指数为39。

Dr. Ana Ćirić is a Principal research fellow at the Institute for Biological Research "Siniša Stanković"-National Institute of Republic of Serbia. The main research topics are antimicrobial activity of biologically active compounds isolated from plants, fungi, invertebrates and synthetic compounds, investigation of the influence of products on the finding of quorum sensing antagonists and biofilm, and the development of new metabolic pathways of certain compounds in the biotransformation process. She participated in 6 projects national and 11 international projects. She has published 204 papers in international peer reviewed journals of high importance: with over 5000 citations; with h-index of 39.



Jasmina Glamočlija

塞尔维亚IBISS植物生理学系首席研究员

Principal Research Fellow at the Department of Plant Physiology,
IBISS-National Institute of Republic of Serbia

塞尔维亚贝尔格莱德大学"Siniša Stanković"生物研究所(IBISS)植物生理学系(真菌学实验室)首席研究员、塞尔维亚真菌学会创始人(2008-2014年任主席)，多个该领域相关国际协会会员。研究方向为制药和农业技术应用的药物研究、天然产品的化学、代谢组学等药理活性。曾入选斯坦福大学2020-2022年最高被引作者名单。参与多个塞尔维亚科技发展部主导项目。

Dr. Jasmina Glamočlija is the Principal Research Fellow at the Department of Plant Physiology (Mycology Lab.), IBISS- National Institute of Republic of Serbia. The scientific research is focused on drug research for pharmaceutical and agro-technological applications, biology of fungi, plants, chemistry of natural products, metabolomics, and pharmacological activities of natural matrices. Dr. Glamočlija is currently on the list of the most cited authors Stanford's list for 2020, 2021 and 2022. She participated more than 11 scientific projects governed by the Ministry of Science and Technological Development, the Republic of Serbia.



王彦春 Wang Yanchun

湖北中医药大学党委常委，中医临床学院党委书记、院长

入选教育部新世纪优秀人才。主要从事针灸防治心脑血管病及神经系统疾病的研究，主持完成国家自然科学基金项目、湖北省自然科学基金“杰青”项目等。

Member of the Standing Committee of the Party Committee of Hubei University of Chinese Medicine, Party Secretary and Dean of School of Clinical Chinese Medicine. He was selected as an Outstanding Talent in the New Century by the Ministry of Education. His research interests include using acupuncture for the prevention and treatment of cardiovascular, cerebrovascular diseases and nervous system diseases. He has presided over and completed projects funded by the Natural Science Foundation of China and the Hubei Provincial Natural Science Foundation "Distinguished Young Scholars" program.



黄 恺 Huang Kai

华中科技大学同济医学院附属协和医院党委常委、副院长，心血管内科教研室主任，同济医学院梨园心血管临床医学中心主任

华中科技大学同济医学院附属协和医院党委常委、副院长，心血管内科教研室主任，同济医学院梨园心血管临床医学中心主任。教育部长江学者特聘教授。主要从事分子心脏病学研究，对冠心病、血脂异常、糖尿病性心脏病和高血压等疾病的临床诊断和治疗有丰富的经验。

Member of the Standing Committee of the Party Committee, Vice President of Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Director of the Department of Cardiovascular Medicine, Director of Liyuan Cardiovascular Clinical Medicine Center, Tongji Medical College. Distinguished Professor and Yangtze River Scholar by the Ministry of Education. He is mainly engaged in molecular cardiology research, and has rich experience in the clinical diagnosis and treatment of coronary heart disease, dyslipidemia, diabetic heart disease and hypertension.



刘吉开 Liu Jikai

中南民族大学药学院学术委员会主任，教授

中南民族大学药学院学术委员会主任，教授。国家杰出青年科学基金获得者。主要研究民族药与药用真菌，其研究团队已成为世界上从事高等真菌化学和生物活性研究具有较大影响的团队之一。

Professor, Director of Academic Committee, School of Pharmaceutical Sciences, South-Central Minzu University. Recipient of the National Science Fund for Distinguished Young Scholars. His is mainly engaged in research on ethnic medicine and medicinal fungi, and leads a team that has become one of the most influential teams in the world in advanced fungal chemical and biological activity research.



刘天罡 Liu Tiangang

武汉大学药学院教授
合成微生物技术湖北省工程实验室主任

武汉大学药学院教授，合成微生物技术湖北省工程实验室主任。主要研究领域为合成生物学、代谢工程、微生物药物高效合成、微生物天然产物高通量挖掘等。

Professor, School of Pharmaceutical Sciences, Wuhan University, Director of Hubei Engineering Laboratory of Synthetic Microbial Technology. His main research interests are synthetic biology, metabolic engineering, efficient synthesis of microbial drugs, and high-throughput mining of microbial natural products.



张冬卉 Zhang Donghui

湖北大学生命科学学院教授

湖北大学生命科学学院教授。主要研究干细胞生物学、组织工程及微器官芯片构建。研究方向包括心肌病新型诊疗方案开发、心肌损伤过程中的心肌保护策略开发、瓣膜钙化的模拟与疗法开发、微器官体外生理系统开发等。

Professor, School of Life Sciences, Hubei University. Her main research areas are stem cell biology, tissue engineering and micro organ chip construction. Her research interests include the development of new diagnosis and treatment protocols for cardiomyopathy, the development of myocardial protection strategies during myocardial injury, the simulation and therapy development of valve calcification, and the development of in vitro physiological systems of microorgans.

八、武创院及创新单元伙伴(按姓氏笔画排序)

WUHAN INNOVATION INSTITUTE AND INNOVATION UNIT PARTNERS

马春辉 武创院纳米抗体产业平台负责人, 武汉纳博生命科技有限公司CEO

Ma Chunhui, Head of WHIID R&D Platform for Nano Antibody Industry, CEO of Wuhan Nano-Boby Life Science and Technology Co., LTD.

王钟秀 “一带一路”国际科学组织联盟(ANSO)秘书处项目专员

Wang Zhongxiu, Project Specialist, the Alliance of International Science Organizations (ANSO)

王慧中 武汉产业创新发展研究院院长助理

Wang Huizhong, Assistant President of Wuhan Institute of Industrial Innovation and Development

瓦阿里 武创院纳米抗体产业平台市场总监

Ali H.D. Wari, Marketing Director of WHIID R&D Platform for Nano Antibody Industry

任习东 武创院创新药物发现与非临床评价服务平台负责人,
湖北天勤生物科技有限公司董事长

Ren Xidong, Head of Innovative Drug Discovery and Non-Clinical Evaluation Service Platform of WHIID, and Chairman of Hubei Topgene Biotechnology Co., LTD.

杜莹莹 武创院生物医用材料器械研究所技术负责人,
华中科技大学生命科学与技术学院副教授

Du Yingying, Technical Director of the WHIID Institute of Biomedical Materials and Devices, Associate Professor at the College of Life Science & Technology, Huazhong University of Science and Technology

杜霖 华信创投总经理

Du Lin, General Manager of Huaxin Venture Capital

肖其磊 湖北广济药业生物技术研究院总经理

Xiao Qilei, General Manager of Hubei Guangji Pharmaceutical Biotechnology Research Institute



张哲宁 济峰资本高级投资经理

Zhang Zhe'ning, Senior Investment Manager of Jifeng Ventures

张超 倚锋资本董事总经理

Zhao Chao, Managing Director of Efung Capital

张冬严 上海吉凯基因医学科技股份有限公司总裁助理

Zhang Dongyan, President Assistant, Shanghai Genechem Co., LTD.

陆冬英 中国科学院上海药物研究所科研与新药推进处副处长

Lu Dongying, Deputy Director, Research and New Drug Promotion Division, Shanghai Institute of Materia Medica, China Academy of Sciences

陈永宁 中国科学院上海药物研究所国际国内合作处顾问

Chen Yongning, Consultant to the Office of International and Domestic Cooperation, Shanghai Institute of Materia Medica, China Academy of Sciences

周璐 马应龙药业集团健康研究院副院长

Zhou Lu, Vice President of Health Research Institute of Mayinglong Pharmaceutical Group

姚远 武汉产业创新发展研究院风控总监

Yao Yuan, Director of Risk Management, Wuhan Institute of Industrial Innovation and Development

曹跃琼 武创院创新靶点药物研究所所长，上海吉凯基因医学科技股份有限公司董事长

Cao Yueqiong, Director of the Institute of Innovative Target Drugs of WHIID, Chairman of Shanghai Genechem Co., LTD.

戴月 武汉产业创新发展研究院院长助理

Dai Yue, Assistant President of Wuhan Institute of Industrial Innovation and Development

魏桐 武汉华大生命科学研究院植物多维组学中心主任科学家

Wei Tong, Chief Scientist, Plant Multidimensional Genomics Center, Wuhan BGI Institute of Life Sciences

参会组织介绍

INTRODUCTION TO PARTICIPATING ORGANIZATIONS



塞尔维亚贝尔格莱德大学“Siniša Stanković”生物研究所：

塞尔维亚贝尔格莱德大学“Siniša Stanković”生物研究所 (IBISS) 是塞尔维亚生物领域最大且最完善的研究所，内设14个院系和3个职能单位。目前共有工作人员317名，其中包括48名课题组长，23名高级研究人员以及58名副高级研究人员，是东欧最大生物学基础研究的机构之一，聚焦分子生物学、生物化学、细胞学、生理学、植物生理学等学科领域以及交叉学科的基础研究。IBISS汇集普通生物学、分子生物学、生态学、化学、生物化学、物理学、数学、医学、药学、林业学、农学等领域专家，各专家团队依据不同项目及科研任务开展合作，利用各自领域的学科优势，促进不同学科的交叉融合，并推动医药、林业、制药、农业、生物技术等基础学科的发展。研究基础设施包括：配备有完整科研设备的专业实验室、温室、实验动物农场、无菌细胞和组织培养实验室（植物和动物）以及水产养殖实验室。IBISS是塞尔维亚具有相当影响力及公认度的应用研究领导者，在过去五年中，共承担塞尔维亚教科部26项科研项目，12项科研基金资助项目，51项其他国家级科研项目，以及24项国际科研项目和15项双边项目，在高影响国际期刊上发表同行评审论文1200余篇，同时是三家国际科学期刊的联合出版商。

Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade (IBISS)

Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade (IBISS) is the largest and most complete research institution for biological sciences in Serbia. It has 14 departments and 3 supporting organs. There are currently 317 staff members, including 48 Project Leaders, 23 Senior Researchers and 58 Deputy Senior researchers. IBISS is an independent research institute founded in 1947, which is dedicated to continuous development and education of scientific research staff, which includes the advanced training of young researchers through various scientific activities. Investigations in the IBISS are primarily focused on fundamental studies in biology including complex inter- and multidisciplinary investigations in molecular biology, biochemistry, cytology, physiology, plant physiology, neurobiology, immunology, genetics, ecology, evolutionary biology, taxonomy, biogeography and the environmental protection. IBISS is a leader in applied research in Serbia with certain influence and public recognition. In the past five years, IBISS has undertaken a total of 26 scientific research projects of the Ministry of Education and Science of Serbia, 12 projects funded by the Research Fund of the Republic of Serbia, 51 other national research projects, 24 international research projects and 15 bilateral projects, and published more than 1,200 peer-reviewed papers in high-impact international journals. IBISS is also the co-publisher of three international scientific journals.

中国科学院上海药物研究所：

中科院上海药物研究所是中国历史最悠久的综合性创新药物研究机构，现有五个国家级研究中心：新药研究国家重点实验室、国家新药筛选中心、中药标准化国家工程实验室、国家化合物样品库、国家中药质量第三方检测（南方）中心，其中，新药研究国家重点实验室连续4次被评为优秀，是药学领域唯一的优秀实验室。上海药物所建成了功能齐全、技术先进、综合集成、无缝衔接、运行高效、国际规范的综合性创新药物研发体系，瞄准国际生命科学发展的前沿领域以及药物研究的重要科学问题，开展创新药物基础和应用基础研究，发展药物研究新理论、新方法和新技术，重点围绕治疗恶性肿瘤、心脑血管系统疾病、神经精神系统疾病、代谢性疾病、自身免疫性疾病及感染性疾病等开展新药研发。自建以来共研制开发新药100余种并投入生产，创制了一批在国内外具有一定影响的创新药物，如抗疟新药蒿甲醚迄今已出口全球20多个国家，为应对全球性卫生挑战做出了重大贡献。

The Shanghai Institute of Materia Medica (SIMM)

The Shanghai Institute of Materia Medica, Chinese Academy of Sciences, is the oldest comprehensive innovative pharmaceutical research institution in China. It has five national-level research centers: The State Key Laboratory of Drug Research, the National Drug Screening Center, the National Engineering Laboratory for the Standardization of Traditional Chinese Medicine, the National Compound Sample Library, and the National Third-Party Testing (South) Center for Quality of Chinese Medicine. Among them, the State Key Laboratory of Drug Research has been rated as excellent for four consecutive times and is the laboratory in the field of pharmaceuticals certified as "excellent". The Shanghai Institute of Materia Medica has established a comprehensive innovative drug development system that is fully functional, technologically advanced, integrated, seamless, efficient, and internationally standardized. It targets the forefront of international life sciences and important scientific issues in drug research, carries out innovative research on fundamental research of innovative drugs and fundamental application research, develops new theories, methods, and technologies in drug research, and focuses on the development of new drugs for the treatment of malignant tumors, cardiovascular and cerebrovascular diseases, neurological and psychiatric diseases, metabolic diseases, autoimmune diseases, and infectious diseases. Since its establishment, the institute has developed more than 100 new drugs and put them into production. It has created a number of innovative drugs with certain influence both domestically and internationally. For example, the new antimalarial drug Artemether has been exported to more than 20 countries worldwide, making a significant contribution to addressing global health challenges.

武汉产业创新发展研究院：

武汉产业创新发展研究院（简称武创院）成立于2021年6月，2022年4月正式启动运行，实行理事会领导下的院长负责制，武汉市人民政府市长任理事长。武创院采取企业化管理、市场化运营，致力于做好“政府不能做、高校院所不愿做、企业做不了，但科技创新又必须要做”的事，紧紧围绕服务武汉建设具有全国影响力的科技创新中心，着力打造科技体制改革、创业投资、技术孵化与成果转化、吸引与集聚人才、知识产权与生产性服务等五大平台，加快建设“国内一流、国际知名”新型研发机构，争做创新创业的集聚者、融合者、催化者、引领者。目前，聚焦光电子信息、生命健康、绿色低碳、前沿交叉等领域创新需求，武创院充分发挥体制机制优势和综合集成平台优势，重点引进和联合国内外一流高校院所、院士专家及领军人才团队、行业核心骨干企业，已组建一批专业研究所、企业联合创新中心、公共服务平台。

Wuhan Institute of Industrial Innovation and Development (WHIID)

Wuhan Institute of Industrial Innovation and Development (referred to as WHIID for short) was established in June 2021, and officially started operation in April 2022. WHIID implements a Presidential Responsibility System under the leadership of the Board which is led by the mayor of Wuhan Municipal People's Government as the Chairman. WHIID adopts enterprise-style management and market-oriented operation, and is committed to "doing things that the government cannot do, the colleges/universities do not do, the market will not do, the enterprises want to do but are unable to do, yet must be done for the sake of scientific and technological innovation", closely focusing on facilitating Wuhan's building of a scientific and technological innovation center with national influence. WHIID makes efforts to build five platforms, namely, scientific and technological institutional reform, venture capital, technology incubation and research finding translation, attracting and gathering talents, intellectual property rights and productive services, so as to accelerate the construction of a "domestically first-class, internationally renowned" new R&D institution, striving to be an aggregator, integrator, catalyst and leader of innovation and entrepreneurship. At present, focusing on the innovation needs in the fields of optoelectronic information, life and health, green and low-carbon, and interdisciplinary frontiers, WHIID has given full play to the advantages of its institution and mechanism and its comprehensive integration platform, focused on introducing and gathering domestic and foreign first-class universities, academicians, experts, leading talent teams and key enterprises in various fields, and has set up a number of professional research institutes, enterprise joint innovation centers and public service platforms.